US/UK/Canada

Share

Contacts

  • Pål Ryfors

    CEO


    Karlavägen 60, 114 49 Stockholm
    0709623669
    http://www.episurf.com
    • Pick a time period -
    Tags ( Active)

    Episurf Medical to present at Redeye Medtech & Diagnostics Event on November 13th, 2024

    Episurf Medical (Nasdaq: EPIS B) will attend Redeye Medtech & Diagnostics Event which is held on November 13th, 2024. The event is arranged by Redeye and the company will be represented by its CEO Pål Ryfors. The format will be a 12-minute presentation followed by an 8-minute Q&A Session. The presentation will be streamed live at 09:50 CET at https://www.redeye.se/events/1016182/redeye-theme-medtech-diagnostics-3 and will also be made available afterwards on our website www.episurf.com. If you would like to attend the event in person, you can register at https://crm.redeye.se/events/

    Interim Report 1 January - 30 September 2024

    · Improvement of financial result through lower cost base and increased revenues · Focus towards expansion of US sales force · Continued progress of 510(k)-process for great toe implant “I am pleased to present a quarterly report in which we seriously demonstrate that our measures positively impact the income statement. In the third quarter, we improved our result by SEK 4.9m compared to the corresponding quarter last year, and we now see that our cost-saving initiatives are yielding results. With increased revenues, we have good opportunities to continue to step into the

    Members of the Nomination Committee for Episurf Medical’s Annual General Meeting in 2025

    In accordance with the decision by the Annual General Meeting, Episurf Medical’s Nomination Committee shall consist of four members. The members are selected by the three largest shareholders in the company that wish to participate in the committee. In addition, the Chairman of the Board is to be appointed to the Nomination Committee. The members of the Nomination Committee shall agree on a chairman/woman of the committee. In accordance with the above principles, the Nomination Committee consists of the following four members: · Ulf Grunander, Chairman of the Board Episurf Medical

    Niles Noblitt, through Sacajo Investments LLC, makes investment in Episurf through an arrangement with CEO Pål Ryfors

    In order to facilitate settlement of an acquisition of 9,526,170 Class B shares in Episurf Medical AB (publ) (“Episurf” or the “Company”) by Sacajo Investments LLC (“Sacajo”), a trust with the Company’s Senior Advisor Niles Noblitt as first member, Sacajo and Pål Ryfors, CEO of Episurf, have agreed that Pål Ryfors shall hold the shares during an interim period. Consequently, Pål Ryfors will acquire 9,526,170 Class B shares in Episurf from Sacajo for a purchase price of SEK 2,286,280.80, corresponding to SEK 0.24 per share. Payment for the shares is made by Pål Ryfors issuing a promissory

    Episurf Medical: Update on 510(k) application for big toe implant

    Episurf Medical (Nasdaq: EPIS B) today provides an update on the company's 510(k) application to the US FDA, for market clearance of the company's implant for treatment of osteoarthritis in the so-called 1st MTP joint in the big toe. During this process, the company has exchanged information with the FDA, and this process will continue shortly. "We are pleased to have come this far in the process. We have in-depth experience of interacting with the FDA, and we know that it is difficult to forecast these processes accurately, but we certainly feel that we are moving forward. We will not

    Episurf Medical to present at Pareto Securities Healthcare Conference on September 19, 2024

    Episurf Medical (Nasdaq: EPIS B) to present at Pareto Securities Healthcare Conference on September 19, 2024. The event is arranged by Pareto and the company will be represented by its CEO Pål Ryfors. Time: 11:05-11:25 CESTFormat: 20 minutes including Q&ALocation: Studio 8, Downtown Camper, Drottninggatan 28, 111 51 Stockholm The presentation slides will be made available afterwards on our website www.episurf.com.

    Episealer® technology to be presented at international scientific congress

    Episurf Medical (Nasdaq: EPIS B) today announces that the Episealer® technology will be presented at the 7th ICRS (International Cartilage Regeneration & Joint Preservation Society) Summit in Catania, Italy, on September 25-27, 2024. The Episealer® technology will be presented at two sessions as part of the scientific program. Dr. Gary Levengood of Sports Medicine South, part of the Northside Health System, GA, USA, has been invited to present his experience using the Episealer® Patellofemoral System, introduced on the US market in 2023. This is the first time usage of the Episealer®

    Episurf Medical announces outcome of the rights issue

    THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, ISRAEL, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUS, REGISTRATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW, IS PROHIBITED, OR OTHERWISE IS UNLAWFUL OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH ACTION. REFER TO THE SECTION "IMPORTANT

    Interim Report 1 January – 31 March 2024

    • Reduced cost base following implementation of restructuring programme• Ongoing regulatory process targeting 510(k)-clearance Episealer® MTP-System• Largest distribution agreement to date in the US with Performance Orthopaedics of the Carolinas, Inc., an exclusive distributor for DePuy Synthes Reconstruction products for North Carolina and South Carolina“During the first quarter, our transition towards a higher degree of distributor sales continued. Of course, this change has affected our sales negatively in the short term, but it is the right step to take to reach out on a broader

    Episurf Medical to present at Life Sciencedagen on March 6, 2024

    Episurf Medical (Nasdaq: EPIS B) will attend Life Sciencedagen which is held on March 6, 2024. The company will be represented by its CEO Pål Ryfors. The presentation will be streamed live at 14:45 CET at www.lifesciencedagen.se  and will also be made available afterwards on our website www.episurf.com. The event takes place at Wallenberg Conference Center, Sahlgrenska Academy, at Medicinareberget in Gothenburg.

    Notice of Annual General Meeting of Episurf Medical AB (publ)

    This English translation of the notice is an unofficial translation of the Swedish original. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.The shareholders in Episurf Medical AB (publ), 556767-0541 (“Episurf” or the “Company”), are hereby summoned to the Annual General Meeting (the “Meeting”) on Tuesday, 9 April 2024, at 15:00 (CEST) at the Company’s office at Karlavägen 60, SE-114 49 Stockholm, Sweden. Entry and registration begin at 14:30 (CEST). The Board of Directors has, pursuant to Chapter 7, Section 4 a of the

    Nomination Committee’s proposal regarding board of directors of Episurf Medical AB for 2024

    Episurf Medical’s Nomination Committee proposes six regular board members without deputies, including the re-election of Ulf Grunander as chairman of the board and the proposed new election of Dr. Jess Lonner as board member, to be confirmed at the annual general meeting. Other board members are proposed for re-election. Ulf Grunander was elected chairman in 2023 and has been a board member since 2021. Other board members proposed for re-election are Board Members Leif Ryd (member since 2009), Christian Krüeger (member since 2016), Laura Shunk (member since 2017) and Annette Brodin Rampe (

    Results from up to 10 years follow-up of Episealer® patients accepted for presentation at international orthopaedic congress

    Episurf Medical (Nasdaq: EPIS B) today announces that the abstract “Survivorship and clinical outcome of a novel personalized metal implant for the treatment of cartilage lesions of the knee”, by Dr.ssa Francesca de Caro has been accepted for a podium presentation at The Partial Knee Meeting 2024. The congress will take place in Antwerp, Belgium, on January 25-26, 2024. The abstract reports on high implant survival rate and good clinical outcome for 22 patients who were treated with Episurf Medical’s personalised implant Episealer® Knee as treatment for chondral and osteochondral defects

    New patent approvals for Episurf Medical

    Episurf Medical (NASDAQ: EPIS B) has during the last months received four additional patent approval notifications. The Indian patent office Intellectual Property India has reported that Episurf has received two new granted patents in India. One is related to implant materials and coatings, while the other is related to Episurf’s damage visualisation process for surgical pre-planning and individualised medical device design. The Australian patent office IP Australia has issued a notice of acceptance for a patent related to the implant-specific drill used for Episurf’s implant technology.

    Early clinical results from Episealer® Talus study presented at scientific congress

    Episurf Medical (Nasdaq: EPIS B) today announces that clinical results for the Episealer® Talus technology have been presented at the 38[th] Congress of the Italian Foot and Ankle Society in Riva Del Garda, Italy, on September 21-22. The presentation with the title “Episealer Talus, an innovative patient-specific metallic implant for the treatment of osteochondral lesions of the talar dome” was held by Dr Marco Di Ponte from the Rizzoli Orthopedic Institute, Italy, and reported on early results from an investigator-initiated study. The study follows 20 patients who received an Episealer®

    Scientific article on Episealer® Talus surgical technique published in Foot & Ankle Clinics

    Episurf Medical (Nasdaq: EPIS B) today announces that an article on the surgical technique for Episurf Medical’s implant system for treatment for osteochondral defects in the ankle joint, Episealer® Talus, has been published in the scientific journal Foot & Ankle Clinics. The publication, with the title “Personalized Resurfacing for Osteochondral Lesions of the Talus”, by F. G.  Usuelli, MD, B. Efrima, MD and Prof. N. van Dijk, covers areas such as the etiology of typical ankle lesions and alternative treatment methodologies, in addition to providing a detailed review of the surgical

    Prospective Episealer® Talus clinical study fully recruited

    Episurf Medical (Nasdaq: EPIS B) today announces that all patients have been recruited to a prospective clinical study on the Episealer Talus® implant, led by Prof. Stefano Zaffagnini, from the Rizzoli Orthopaedic Institute in Bologna, Italy, supported by Dr Massimiliano Mosca and Prof. Niek van Dijk. The study will follow 20 patients who received an Episealer Talus® implant as treatment for osteochondral defects in their ankle joint. Episealer® Talus is Episurf Medical’s CE marked implant technology, intended for the treatment of ankle lesions.  “Our technology for ankle lesions is

    Episurf Medical: Approaching 510(k) submission for big toe implant

    Episurf Medical (NASDAQ: EPIS B) today provides an update on the planned 510(k) filing to the US FDA for the company’s implant for the 1[st] MTP joint of the big toe. The company plans to file the 510(k) submission for US market clearance during the coming weeks. The company aims to receive clearance to be able to launch the product on the US market during 2024. The company is currently assessing various options for commercialization strategy, including independent distributors and technology licensing. The implant is intended to treat osteoarthritis (hallux rigidus) in the big toe. It

    Episurf Medical: First commercial case in the US scheduled

    Episurf Medical (Nasdaq: EPIS B) today announces that the company’s first commercial case in the US has been scheduled for surgery. This is also the first case ever with the newly introduced product Episealer® Patellofemoral System. The product is a fully individualized implant system for patients with isolated osteoarthritis of the patellofemoral joint in the knee. Personalized implants for both sides of the joint, femur and patella, preserving as much bone and cartilage as possible by treating only the damaged areas of the joint, are designed uniquely for each individual patient. 510(k)

    Results from the use of Episealer® accepted for publication in scientific journal

    Episurf Medical (Nasdaq: EPIS B) today announces that results from a follow-up study on the Episealer® knee implant have been accepted for publication (peer-reviewed) in the Journal of Experimental Orthopaedics. The article, with the title “2-year results of middle-aged patients with two-compartment cartilage lesions in one knee treated with two patient specific metal implants”, by Daniel Aaron den Toom, Markus Rieke, Allaeldin Elbadawi and Clemens Kösters, focuses on the clinical outcome from follow-up of patients treated with two implants in the same knee. The patients have been followed-

    Episurf Medical: Strategy update to take the next commercial steps and improve financial results

    Episurf Medical (Nasdaq: EPIS B) today announces that the company is implementing a strategic focus that brings an increased focus on the US market, as well as a transition to a distributor model for other key markets. The company sees great opportunities for continued commercialization within selected market segments. The strategic focus means: · Operational measures to significantly improve the company's financial position and running costs. · Accelerate the path towards, and increase transparency for, operational profitability. · Increased focus on distributor sales and

    Episurf Medical’s first EPIC-Knee surgery in Canada scheduled

    Episurf Medical (NASDAQ: EPIS B) today announces that the first surgery in Canada within the company’s IDE Clinical Trial, EPIC-Knee: Episealer® Knee System IDE Clinical Study, is scheduled. The randomised controlled IDE study is currently ongoing in the USA/Canada and Europe, and surgeries have this far been performed in Tennessee and California in the US, as well as in Germany. The end goal with the study is an FDA PMA application for US market approval the Episealer® Knee implant. "This is a milestone in this important study. We have had challenges with the speed of recruitment for

    Episurf Medical to present at Innovative Orthopedics hosted by Redeye on March 21st, 2023

    Episurf Medical (Nasdaq: EPIS B) will present at Innovative Orthopedics on March 21st, 2023. The event is arranged by Redeye and will be streamed live. The company will be represented by its CEO Pål Ryfors. Time: 11:20 CET Link to the livestream:  https://www.redeye.se/events/869691/innovative-orthopedic-1 The presentation will also be made available afterwards on our website www.episurf.com.

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media